Ocugen (NASDAQ:OCGN) Issues Earnings Results

Ocugen (NASDAQ:OCGN) issued its quarterly earnings data on Wednesday. The company reported ($0.06) EPS for the quarter, hitting analysts’ consensus estimates of ($0.06), FiscalAI reports. The firm had revenue of ($0.19) million during the quarter, compared to analyst estimates of $0.86 million. Ocugen had a negative return on equity of 491.22% and a negative net margin of 1,192.18%.

Here are the key takeaways from Ocugen’s conference call:

• Enrollment is complete for the OCU400 Phase 3 liMeliGhT trial (140 patients); top-line 12‑month data are expected in Q1 2027 and a rolling BLA submission is planned to begin in Q3 2026 with commercialization targeted in 2027.
• Interim Phase 2 data for OCU410 in geographic atrophy showed a 46% reduction in lesion growth at 12 months (P=0.015) and a 50% responder rate, with full Phase 2 data due this month and Phase 3 initiation planned for 2026.
• The Stargardt program (OCU410ST) remains ahead of schedule, benefited from a peer‑reviewed Phase 1 publication and CHMP confirmation that the single U.S. trial can support an EMA application, with pivotal topline data expected in 2Q 2027.
• Cash on hand extends runway only into Q4 2026 after a recent $22.5M raise, with an extension to Q2 2027 contingent on full exercise of $30M of warrants, indicating near‑term financing risk before commercialization.
• Management and business development were strengthened in 2025 (new commercial, finance, and operations hires), plus a regional licensing deal for OCU400 in Korea and the creation of the Ocucelix subsidiary to pursue non‑core assets, supporting commercialization and value‑creation plans.

Ocugen Stock Performance

Ocugen stock traded up $0.09 during mid-day trading on Wednesday, reaching $1.95. 5,951,550 shares of the company’s stock were exchanged, compared to its average volume of 5,666,241. The business’s fifty day simple moving average is $1.56 and its 200 day simple moving average is $1.41. The company has a quick ratio of 1.85, a current ratio of 1.85 and a debt-to-equity ratio of 8.04. Ocugen has a one year low of $0.52 and a one year high of $1.97. The firm has a market capitalization of $607.46 million, a PE ratio of -8.84 and a beta of 2.75.

Institutional Investors Weigh In On Ocugen

A number of hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. boosted its holdings in shares of Ocugen by 3.1% in the 3rd quarter. Vanguard Group Inc. now owns 15,223,585 shares of the company’s stock worth $24,814,000 after buying an additional 450,904 shares during the last quarter. Millennium Management LLC raised its position in Ocugen by 29.7% in the fourth quarter. Millennium Management LLC now owns 5,396,417 shares of the company’s stock worth $7,285,000 after acquiring an additional 1,234,268 shares during the period. State Street Corp raised its position in Ocugen by 193.6% in the fourth quarter. State Street Corp now owns 3,978,738 shares of the company’s stock worth $5,371,000 after acquiring an additional 2,623,361 shares during the period. Geode Capital Management LLC boosted its stake in Ocugen by 3.9% in the fourth quarter. Geode Capital Management LLC now owns 3,819,242 shares of the company’s stock valued at $5,159,000 after acquiring an additional 142,050 shares during the last quarter. Finally, Marshall Wace LLP bought a new position in shares of Ocugen during the 4th quarter valued at approximately $3,417,000. 10.27% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on OCGN. Chardan Capital reaffirmed a “buy” rating and set a $7.00 target price on shares of Ocugen in a research report on Tuesday, January 20th. Weiss Ratings restated a “sell (e+)” rating on shares of Ocugen in a research note on Thursday, January 22nd. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $7.00.

About Ocugen

Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing gene therapies to treat rare inherited retinal diseases, as well as vaccines designed to address unmet needs in infectious diseases. Headquartered in Malvern, Pennsylvania, the company applies its proprietary gene therapy platform to create novel treatments aimed at preserving and restoring vision, while leveraging strategic partnerships to broaden its vaccine pipeline.

In its gene therapy portfolio, Ocugen is advancing multiple programs targeting retinal disorders.